Tang Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Tang Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-220,000	Closed	-$29M	–	220
2025 Q1	$29M	Sell	220,000 -80,000	-27%	-$9.97M	1.61%	13
2024 Q4	$25.1M	Hold	300,000	–	–	1.66%	14
2024 Q3	$22M	Hold	300,000	–	–	1.57%	17
2024 Q2	$20.5M	Buy	300,000 +150,000	+100%	+$10.4M	2.09%	12
2024 Q1	$10.4M	Sell	150,000 -70,000	-32%	-$4.81M	1.08%	29
2023 Q4	$15.8M	Sell	220,000 -80,000	-27%	-$4.6M	1.46%	18
2023 Q3	$15.6M	Hold	300,000	–	–	2.21%	12
2023 Q2	$19M	Hold	300,000	–	–	2.8%	10
2023 Q1	$16.2M	Buy	300,000 +60,000	+25%	+$2.9M	2.42%	13
2022 Q4	$12.7M	Sell	240,000 -400,000	-63%	-$20M	1.85%	17
2022 Q3	$29.8M	Sell	640,000 -60,000	-9%	-$3.13M	3.65%	6
2022 Q2	$40M	Hold	700,000	–	–	6.06%	5
2022 Q1	$42.8M	Buy	+700,000	New	+$36.4M	8.57%	2
2020 Q2	–	Sell	-41,444	Closed	-$637K	–	26
2020 Q1	$637K	Buy	+41,444	New	+$900K	0.09%	22

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Tang Capital Management's ITCI Position: Q2 2025 in Review

Tang Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 220,000 shares — an estimated $29M sold.

Tang Capital Management first reported a position in ITCI in Q1 2020 and held it in 14 quarters. The position peaked at $42.8M in Q1 2022. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Tang Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Tang Capital Management sold 220,000 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $29M.
Tang Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2020 and held it in 14 quarters.
Tang Capital Management's Intra-Cellular Therapies Inc. position peaked at $42.8M in Q1 2022.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Tang Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.